Navigation Links
Novus Scientific Announces a New U.S. Patent for a Mesh Implant Comprising Two Different Resorbable Materials with Different Degradation Times and Specific Mechanical Behaviours; U.S. Patent No. -- 8,083,755
Date:12/27/2011

SINGAPORE, Dec. 27, 2011 /PRNewswire/ -- The Intellectual Property portfolio of TIGR® Matrix Surgical Mesh has been further complimented with the granting of a second U.S. patent related to material degradation and mechanical behaviour. TIGR® Matrix was developed based on the hypothesis that soft tissue positively remodels in response to the stimulus of increased mechanical load – a process known as 'mechanotransduction', which is the physiological process by which cells sense and respond to mechanical loads. This key feature contributes to the functional regenerated tissue that ultimately replaces the degraded mesh, as shown in preclinical trials. (ref:http://www.springerlink.com/content/c033k26015677312/).

The first U.S. patent covered the interlocking structure of a knitted mesh implant. The mechanotransductional function of TIGR® Matrix is now further protected.

Roger Johansson (Ph.D.) – Vice President Sweden said: "This is a step toward protecting the basic underlying technology behind TIGR® Matrix Surgical Mesh. To have it safely on file alongside our other U.S. and European patents increases our stake in the niche market of which we are sole initiator thus far, and represents real value to Novus Scientific and the future of TIGR® Matrix."

TIGR® Matrix Surgical Mesh is the World's 1st Long-Term Resorbable, (100% Absorbable) Synthetic Mesh indicated for reinforcement of soft tissue where weakness exists. Its unique patented dual-fiber construction is designed for gradually increasing mechanical compliance, making it strong for 6 months and gone in 3 years. The US Food and Drug Administration (FDA) gave the company 510(k) clearance to market TIGR® Matrix Surgical Mesh in February 2010. In August 2011 Novus Scientific received CE Mark approval from BSI for TIGR® Matrix Surgical Mesh in Europe.

TIGR® Matrix Surgical Mesh is available for sale in the U.S. and selected countries in Europe and Asia.

About Novus Scientific
Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices.

For comprehensive information vist our PRESSROOM: http://www.mynewsdesk.com/pressroom/novus-scientific

TIGR® is a trademark of Novus Scientific Pte. Ltd

 

CONTACT:  
Roger Johansson: +46 (0)73 396 55 45-  roger.johansson@novusscientific.com

 

 


'/>"/>
SOURCE Novus Scientific
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
2. Novus Scientific Announces the Sales Launch for TIGR™ Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
3. Novus Scientific and Singapore Association of Plastic Surgeons (SAPS) Host the Inaugural Event of SOFTISSUE - The Issue of Soft Tissue, Featuring James J. Chao, M.D., FACS, Professor of Plastic Surgery and Orthopedic Surgery, University of Califor
4. Novus Scientific Announces the Worlds 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
7. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
8. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
9. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
10. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
11. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan. 17, 2017 Secretary of Health Dr. ... Secretary Gary Tennis are warning Pennsylvanians of ... recent overdose deaths from the drug in ... intended to sedate large animals and is not meant ... comes into contact with it," Secretary Murphy said. "It,s ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets ... Materials: 2017 - 2024" report to their offering. ... This new report revisits ... report that was issued in May of 2015. Self-healing is an ... our previous analysis we projected a market potential of $2.7 billion ...
(Date:1/17/2017)... The Global Nebulizers Market is poised to ... next decade to reach approximately $1698.68 million by 2025. ... witnessing include rapidly growing demand in emerging regions, increasing ... products and online marketing strategies by key players. ... into pneumatic nebulizers, ultrasonic nebulizers and mesh nebulizers. Pneumatic ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... Visually learn ... one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive sweating and hyperhidrosis are common ... created this infographic to explain the seven types of hyperhidrosis. This visual creates ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for Cancer Research, ... official endurance training and fundraising team, to compete in the Boston Marathon on April ... to finish the world’s oldest annual marathon to join Team V and support the ...
(Date:1/18/2017)... Park, KS (PRWEB) , ... January 18, 2017 ... ... managed firm offering asset protection and financial planning services to families and business ... a charity event aimed at supporting children with developmental disabilities. , The Lakemary ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. Hennessy Associates, Inc., ... Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, ... biosimilars through thought leader interaction in, live video and interactive digital platforms. , ...
(Date:1/18/2017)... VA (PRWEB) , ... January 18, 2017 , ... Floundering ... American Heart Month and the perfect time for a reset. The U.S. Apple Association ... studies to combat many of the factors that contribute to heart disease. , The ...
Breaking Medicine News(10 mins):